selinexor
Addition of Selinexor to Standard Chemotherapy Disappoints in Phase II Trial
Leah SherwoodMyelodysplastic Syndromes | February 2, 2023
The trial examined selinexor's effect on treatment outcomes in patients with AML and high-risk MDS.
Read More
EC Grants Full Marketing Authorization to Selinexor for Relapsed Myeloma
Leah SherwoodMyeloma | November 16, 2022
The European Commission (EC) has granted marketing authorization for selinexor, an oral exportin 1 inhibitor...
Read More
Three-Gene Signature Predicts Response to Selinexor in MM
Leah SherwoodMyeloma | November 22, 2022
The genetic signature consists of the genes WNT10A, DUSP1, and ETV7...
Read More
Advertisement
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |